plck psrc (Cell Signaling Technology Inc)
Cell Signaling Technology Inc is a verified supplier 
Cell Signaling Technology Inc manufactures this product 
96
Structured Review
Cell Signaling Technology Inc
plck psrc
Plck Psrc, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 931 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plck+psrc/Phospho-Src+Family+(Tyr416)+Rabbit+mAb/pm38973320-344-37-39
Average 96 stars, based on 931 article reviews
Plck Psrc, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 931 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plck+psrc/Phospho-Src+Family+(Tyr416)+Rabbit+mAb/pm38973320-344-37-39
Average 96 stars, based on 931 article reviews
plck psrc - by Bioz Stars,
2026-09
96/100 stars
Images
Related Articles
Concentration Assay:Article Title: Development of an Orally Bioavailable LCK PROTAC Degrader as a Potential Therapeutic Approach to T-Cell Acute Lymphoblastic Leukemia. Article Snippet: Despite significant advances over recent years, the treatment of T cell acute lymphoblastic leukemia (T-ALL) remains challenging.. We have recently shown that a subset of T-ALL cases exhibited constitutive activation of the lymphocyte-specific protein tyrosine kinase (LCK) and were consequently responsive to treatments with LCK inhibitors and degraders such as dasatinib and dasatinib-based PROTACs.. Here we report the design, synthesis and in vitro/vivo evaluation of SJ45566, a potent and orally bioavailable LCK PROTAC. Blocking Assay:Article Title: Development of an Orally Bioavailable LCK PROTAC Degrader as a Potential Therapeutic Approach to T-Cell Acute Lymphoblastic Leukemia. Article Snippet: Despite significant advances over recent years, the treatment of T cell acute lymphoblastic leukemia (T-ALL) remains challenging.. We have recently shown that a subset of T-ALL cases exhibited constitutive activation of the lymphocyte-specific protein tyrosine kinase (LCK) and were consequently responsive to treatments with LCK inhibitors and degraders such as dasatinib and dasatinib-based PROTACs.. Here we report the design, synthesis and in vitro/vivo evaluation of SJ45566, a potent and orally bioavailable LCK PROTAC. |